AI assistant
Tempest Therapeutics, Inc. — Director's Dealing 2021
Jun 30, 2021
34632_dirs_2021-06-29_cfb631dc-ef71-48b1-8b61-8b658252df81.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Millendo Therapeutics, Inc. (TPST)
CIK: 0001544227
Period of Report: 2021-06-25
Reporting Person: Lorenzo Pierre (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-25 | Common Stock | A | 53 | — | Acquired | 53 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-25 | Stock Option (Right to Buy) | $5.9 | A | 4830 | Acquired | 2030-11-15 | Common Stock (4830) | Direct |
| 2021-06-25 | Stock Option (Right to Buy) | $10.25 | A | 1234 | Acquired | 2031-03-09 | Common Stock (1234) | Direct |
| 2021-06-25 | Stock Option (Right to Buy) | $26.4 | A | 48535 | Acquired | 2031-04-28 | Common Stock (48535) | Direct |
Footnotes
F1: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc."
F2: One-fourth of the shares underlying this option vest on November 16, 2021, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service.
F3: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service.
F4: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of Closing, June 25, 2021, subject to the reporting person's continued service.